Verici Dx PLC Notice of Results (7580K)
06 Septiembre 2021 - 1:00AM
UK Regulatory
TIDMVRCI
RNS Number : 7580K
Verici Dx PLC
06 September 2021
Verici Dx plc
("Verici Dx" or the "Company")
Notice of Results
Investor Briefing
Verici Dx plc (AIM: VRCI), a developer of advanced clinical
diagnostics for organ transplant, announces that it will release
its unaudited results for the six-month period to 30 June 2021 on
Monday 13 September 2021.
Investor briefing
Sara Barrington, Chief Executive Officer, and David Anderson,
Chief Financial Officer, will provide a live presentation relating
to the Half Year Results via the Investor Meet Company platform on
Monday 13 September 2021 at 16:30hrs BST.
The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via your
Investor Meet Company dashboard up until 09:00hrs the day before
the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add
to meet VERICI DX PLC via:
https://www.investormeetcompany.com/verici-dx-plc/register-investor
Investors who already follow Verici Dx plc on the Investor Meet
Company platform will automatically be invited.
Enquiries:
Verici Dx www.v ericidx .com
Sara Barrington, CEO Via Walbrook PR
Julian Baines, Chairman
N+1 Singer (Nominated Adviser & Broker) Tel: 020 7496 3000
Aubrey Powell / Justin McKeegan / Tom
Salvesen
Walbrook PR Limited Tel: 020 7933 8780 or vericidx@walbrookpr.com
Paul McManus / Sam Allen Mob: 07980 541 893 / 07502 558 258
About Verici Dx plc www.vericidx.com
Verici Dx is developing and commercialising tests to understand
how a patient will respond and is responding to organ transplant,
with an initial focus on kidney transplants. The body's own immune
system poses a threat to a successful transplant or graft.
Patients' immune systems differ in how they respond to the presence
of the transplanted organ and in conjunction with biological
pathways. Our products and solutions are underpinned by extensive
scientific research producing RNA signatures to determine the risk
and diagnosis of acute rejection, chronic injury and ultimately
failure of the transplant. These RNA signatures also provide
valuable information to clinicians as to the optimal strategy for
immunosuppressive and other therapies for the most successful
treatment to ensure graft acceptance with the least amount of side
effects.
The foundational research was driven by a deep understanding of
cell-mediated immunity and is enabled by access to expertly curated
collaborative studies in highly informative cohorts in kidney
transplant.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORLAMPTMTJMBLB
(END) Dow Jones Newswires
September 06, 2021 02:00 ET (06:00 GMT)
Verici Dx (LSE:VRCI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Verici Dx (LSE:VRCI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024